Medline Inc. (MDLN) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call shows strong organic growth, positive guidance adjustments, and strategic expansions, such as new Prime Vendor signings and product launches. The company is effectively managing tariff impacts and maintaining financial health with stable leverage. Despite some uncertainties in the Q&A, like commodity impact quantification, the overall sentiment is positive due to robust growth drivers, strategic initiatives, and a strong market position, suggesting a positive stock price movement.

Key Financial Performance

Net Sales $7.4 billion, up 11% year-over-year. Growth was primarily organic with minimal contribution from foreign currency changes. The quarter had one less business day compared to the prior year, which created a 2 percentage point headwind.

Medline Brand Segment Net Sales $3.5 billion, up 6% year-over-year or 8% adjusted for days. Growth driven by strong performance in surgical solutions and frontline care.

Surgical Solutions Net Sales $1.6 billion, up 7% year-over-year. Growth led by continued strong performance in surgical kitting.

Front Line Care Net Sales $1.6 billion, up 6% year-over-year. Growth driven by robust demand across multiple product divisions, including exam gloves and personal care.

Lab & Diagnostics Net Sales $293 million, up 1% year-over-year. Double-digit core lab growth was offset by seasonality related to softer respiratory virus testing.

Supply Chain Solutions Net Sales $3.9 billion, up 15% year-over-year or 17% adjusted for days. Growth driven by new customer implementations and existing customer growth.

U.S. Acute Care Sales $5.1 billion, up 12% year-over-year. Growth driven by new Prime Vendor customers and solid same-store sales growth.

U.S. Non-Acute Sales $1.7 billion, up 7% year-over-year. Growth supported by strong existing customer growth and new customer signings in post-acute, surgery centers, and physician offices.

International Sales $495 million, up 10% year-over-year. Growth due to foreign currency and volume growth in Canada and Europe.

Adjusted EBITDA $776 million, down 11% year-over-year. Decline due to higher costs, including $85 million in incremental tariffs and operational investments, partially offset by higher net sales volumes.

Adjusted EBITDA Margin 11%, down 250 basis points year-over-year. Decline driven by higher costs and operational investments.

Medline Brand Adjusted EBITDA $765 million, down $65 million year-over-year. Adjusted EBITDA margin declined 330 basis points to 22.1%, primarily due to higher import costs from tariffs.

Supply Chain Solutions Adjusted EBITDA $187 million, up $5 million year-over-year. Adjusted EBITDA margin declined 60 basis points to 4.8%, primarily due to customer mix and operational costs.

Free Cash Flow $316 million. Driven by net income excluding non-cash items, partially offset by increased trade accounts receivable, inventory, and CapEx investments.

CapEx $96 million. Investments included enhancements and automation in distribution centers and capacity expansion in Mexico kitting manufacturing.

Cash and Cash Equivalents $2.2 billion. Net leverage remained at 3.1x.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Pick Pack Pro: Introduced as a new automation fulfillment system in Montgomery, New York distribution center, combining advanced technologies to improve speed, accuracy, and reliability for health plan customers.

Mpower: AI-enabled digital supply chain control tower designed in partnership with Microsoft. Added several customers to the pilot in Q1, reaching 10 in total, with plans to expand rollout in Q2 and offer to most acute care customers by year-end.

Prime Vendor customer in Canada: Signed first Prime Vendor customer in Canada, partnering with Mohawk Medbuy Corporation to serve 9 acute member hospitals in Southwestern Ontario. Implementation to start in the second half of 2026.

Symbotic partnership: Announced partnership with Symbotic to deploy an AI-powered robotic platform for automating picking, storage, and retrieval of bulk items. Pilot to begin next year at the Ohio distribution center.

Supply chain enhancements: Strengthened manufacturing and distribution footprint, maintaining robust inventory levels to support customers amid global complexities. Approximately 90% of Medline brand products are now multi-sourced, up 10 percentage points from 5 years ago.

Investment in next-generation supply chain technology: Focused on evolving and investing in supply chain technology to enhance resiliency and regulatory compliance, including partnerships and automation.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Higher Cost of Goods Sold: The company experienced an 11% decline in adjusted EBITDA due to higher costs of goods sold, including incremental tariffs and operational investments.

Tariffs Impact: Incremental tariffs contributed to an $85 million increase in costs, with a net impact of $120 million, affecting profitability.

Geopolitical Uncertainty: The company highlighted risks from geopolitical uncertainty, particularly in the Middle East, which could lead to rising oil prices and increased costs for petroleum-based products.

Supply Chain Disruptions: The company is navigating a complex global operating environment with potential supply chain disruptions, requiring rigorous supply chain and regulatory discipline.

Rising Oil Prices: Rising oil prices due to the Middle East conflict are expected to increase costs for domestic freight and petroleum-based products, impacting profitability in Q2 and Q3.

Inflationary Pressures: Inflationary costs for raw materials like nitrile exam gloves, resins, and plastics are expected to impact the P&L in late Q2 or early Q3.

Operational Investments: Continued operational investments to support customer demand are creating headwinds for profitability.

Regulatory Compliance: Maintaining regulatory compliance and product quality in a complex global supply chain environment requires significant resources and discipline.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Full Year 2026 Organic Sales Growth Guidance: Raised to a range of 8.5% to 9.5% from the previous range of 8% to 9%, reflecting strong same-store sales growth and steady healthcare utilization and procedural volumes.

Full Year Adjusted EBITDA Guidance: Maintained at $3.5 billion to $3.6 billion, with expectations of favorability from lower tariff rates offset by continued investments in operations, sales, and IT, as well as headwinds from rising oil prices.

Quarterly Adjusted EBITDA Growth: Sequential adjusted EBITDA growth expected in the second half of the year as sales grow and benefits from mitigation actions and tariffs materialize.

Middle East Conflict Impact: Minimal impact expected on top-line sales due to limited exposure in the region. Input cost increases anticipated for petroleum-based products, with inflationary costs expected to hit P&L in late Q2 or early Q3.

Operational Investments: Continued investments in operations, sales, and IT to support customer demand, particularly in Q2, with benefits expected in the second half of the year.

New Customer Signings and Growth: Strong momentum from $2.4 billion in 2025 new customer signings and solid same-store sales growth, with additional multichannel new signings in Q1 2026.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:How much lead time is typically given to clients and manufacturer partners for price increases?

A:Typically, clients and manufacturer partners are notified about 45 to 60 days in advance of price increases.

Q:What is the company's guidance on organic revenue and adjusted EBITDA for the year?

A:The company raised its organic revenue guidance to 8.5% to 9.5% for the year and maintained its adjusted EBITDA guidance at $3.5 billion to $3.6 billion.

Q:What are the company's expectations regarding the Middle East conflict's impact on costs?

A:The company is monitoring the situation and has not yet decided to raise prices. They are evaluating the impact on costs such as nitrile hand gloves, resins, and plastics, and will take action as needed.

Q:What details were provided about Prime Vendor signings in the quarter?

A:The company saw a strong start to the year in new Prime Vendor signings and expects to achieve its goal of $1 billion in new signings. However, specific quarterly numbers were not disclosed.

Q:What were the key drivers of profitability in the Supply Chain Solutions business?

A:Strong top-line growth of over 15% was driven by same-store sales growth and new customer implementations. EBITDA was slightly behind expectations due to mix and investments in the business.

Q:What is the company's approach to mitigating tariff impacts?

A:The company focuses on multiple sourcing options, buying inventory in advance, and leveraging its playbook to mitigate challenges before passing costs to customers.

Q:What are the company's plans for new product launches?

A:The company launched forced air warming in the first quarter and plans to add more categories throughout the year. The focus is on mitigating current challenges and driving value for customers.

Q:What trends are being observed in utilization and spending?

A:Utilization was stable in the first quarter, but some softening is expected in the back half of the year due to reimbursement cuts and reduced access to insurance.

Q:What are the key drivers for the Medline Brand and Supply Chain Solutions businesses?

A:Medline Brand growth was driven by strong performance in Surgical Solutions and core Lab & Diagnostics. Supply Chain Solutions growth was driven by same-store sales and new customer signings.

Q:What is the company's inventory strategy and how does it relate to inflationary pressures?

A:The company carries about 80 days of inventory, with more in the Medline Brand side. Inflationary pressures from tariffs and Middle East impacts are being managed through inventory strategies and operational investments.

Q:What is the impact of rising commodity inputs on the Medline Brand portfolio?

A:The company did not quantify the impact but noted that nitrile exam gloves, plastics, and resins are the major categories affected. The Middle East impact is expected to be offset by tariff favorability.

Q:What is the significance of the first Prime Vendor partnership in Canada?

A:The partnership is seen as an opportunity to change the dynamics of the Canadian market and is in addition to the $1 billion U.S. Prime Vendor goal.

Q:What is the company's focus for the Lab & Diagnostics franchise?

A:The focus is on the $25 billion TAM in physician office and acute care labs, with strong growth in core lab business and Medline Brand convertible opportunities.

Q:What updates were provided on dental and animal health initiatives?

A:The company is building a playbook for dental in Canada and expanding Medline Brand categories in animal health, focusing on manufacturing medical supplies rather than distribution.

Q:What are the company's AI and robotics initiatives?

A:The company is leveraging AI through Mpower for supply chain analytics and robotics like AutoStore and Symbotic to improve warehouse efficiency and throughput.

Q:What is the company's outlook on tariffs and leverage?

A:The company expects tariffs to return to pre-SCOTUS levels by late July and is prioritizing organic growth and strategic M&A while maintaining leverage at 3.1x.

Q:What is the competitive landscape and pipeline for new customer wins?

A:The company sees robust opportunities with 50% of top health systems not yet customers. Its differentiated value proposition positions it well against competitors.

Q:Review of Unclear Management Responses

A:Management avoided providing specific numbers for Prime Vendor signings in the quarter, citing variability and lumpiness. Additionally, they did not quantify the impact of rising commodity inputs on the Medline Brand portfolio, stating that only a portion of costs are affected.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

MDLN Transcript

Medline Inc. (MDLN) Q1 2026 Earnings Call Transcript

Positive5-6

Medline Inc. (MDLN) Q4 2025 Earnings Call Transcript

Positive2-25

The earnings call summary indicates strong financial performance with significant contract wins and optimistic guidance for 2026. The company is actively managing tariff impacts and pursuing growth in Medline Brand products and M&A opportunities. Despite some vague responses, the overall sentiment from the Q&A suggests confidence in market share gains and operational efficiencies. These factors, coupled with realistic guidance and strategic initiatives, are likely to positively influence the stock price in the short term.

Medline Inc. (MDLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Neutral1-14

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.